Immunotherapy for pancreatic cancer
US8613916B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Oct 6, 2009 |
| Grant date | Dec 24, 2013 |
| Priority date | — |
| Expiry date | May 6, 2030 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC12N2501/599
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention provides an immunotherapeutic agent and immunotherapy allowing the extension of the survival time of patients with pancreatic cancer. The immunotherapy of the present invention is characterized by comprising the steps of culturing peripheral blood lymphocytes of a patient with pancreatic cancer by stimulating the lymphocytes with an anti-CD3 antibody and an anti-CD52 antibody, thereby to obtain an immunotherapeutic agent, and administering at least four infusions of the resultant immunotherapeutic agent to the same patient, wherein each of the infusions of the immunotherapeutic agent comprises at least 15×109 cells of activated lymphocytes, the percentage of CD3− CD56+ NK cells in the activated lymphocytes is at least 30%, and the administration of the immunotherapeutic agent is begun for the patient who is in at least one state of two or more particular immunocompromised states.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.